Cargando…

Integrated genetic and epigenetic analysis of myxofibrosarcoma

Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by an infiltrative growth pattern and a high local recurrence rate. Here we report the genetic and epigenetic landscape of MFS based on the results of whole-exome sequencing (N = 41), RNA sequencing (N = 29), and methylation...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Koichi, Hosoda, Fumie, Arai, Yasuhito, Nakamura, Hiromi, Hama, Natsuko, Totoki, Yasushi, Yoshida, Akihiko, Nagai, Momoko, Kato, Mamoru, Arakawa, Erika, Mukai, Wakako, Rokutan, Hirofumi, Kawai, Akira, Tanaka, Sakae, Shibata, Tatsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050269/
https://www.ncbi.nlm.nih.gov/pubmed/30018380
http://dx.doi.org/10.1038/s41467-018-03891-9
_version_ 1783340297680322560
author Ogura, Koichi
Hosoda, Fumie
Arai, Yasuhito
Nakamura, Hiromi
Hama, Natsuko
Totoki, Yasushi
Yoshida, Akihiko
Nagai, Momoko
Kato, Mamoru
Arakawa, Erika
Mukai, Wakako
Rokutan, Hirofumi
Kawai, Akira
Tanaka, Sakae
Shibata, Tatsuhiro
author_facet Ogura, Koichi
Hosoda, Fumie
Arai, Yasuhito
Nakamura, Hiromi
Hama, Natsuko
Totoki, Yasushi
Yoshida, Akihiko
Nagai, Momoko
Kato, Mamoru
Arakawa, Erika
Mukai, Wakako
Rokutan, Hirofumi
Kawai, Akira
Tanaka, Sakae
Shibata, Tatsuhiro
author_sort Ogura, Koichi
collection PubMed
description Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by an infiltrative growth pattern and a high local recurrence rate. Here we report the genetic and epigenetic landscape of MFS based on the results of whole-exome sequencing (N = 41), RNA sequencing (N = 29), and methylation analysis (N = 41), using 41 MFSs as a discovery set, and subsequent targeted sequencing of 140 genes in the entire cohort of 99 MFSs and 17 MFSs' data from TCGA. Fourteen driver genes are identified, including potentially actionable therapeutic targets seen in 37% of cases. There are frequent alterations in p53 signaling (51%) and cell cycle checkpoint genes (43%). Other conceivably actionable driver genes including ATRX, JAK1, NF1, NTRK1, and novel oncogenic BRAF fusion gene are identified. Methylation patterns cluster into three subtypes associated with unique combinations of driver mutations, clinical outcomes, and immune cell compositions. Our results provide a valuable genomic resource to enable the design of precision medicine for MFS.
format Online
Article
Text
id pubmed-6050269
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60502692018-07-23 Integrated genetic and epigenetic analysis of myxofibrosarcoma Ogura, Koichi Hosoda, Fumie Arai, Yasuhito Nakamura, Hiromi Hama, Natsuko Totoki, Yasushi Yoshida, Akihiko Nagai, Momoko Kato, Mamoru Arakawa, Erika Mukai, Wakako Rokutan, Hirofumi Kawai, Akira Tanaka, Sakae Shibata, Tatsuhiro Nat Commun Article Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by an infiltrative growth pattern and a high local recurrence rate. Here we report the genetic and epigenetic landscape of MFS based on the results of whole-exome sequencing (N = 41), RNA sequencing (N = 29), and methylation analysis (N = 41), using 41 MFSs as a discovery set, and subsequent targeted sequencing of 140 genes in the entire cohort of 99 MFSs and 17 MFSs' data from TCGA. Fourteen driver genes are identified, including potentially actionable therapeutic targets seen in 37% of cases. There are frequent alterations in p53 signaling (51%) and cell cycle checkpoint genes (43%). Other conceivably actionable driver genes including ATRX, JAK1, NF1, NTRK1, and novel oncogenic BRAF fusion gene are identified. Methylation patterns cluster into three subtypes associated with unique combinations of driver mutations, clinical outcomes, and immune cell compositions. Our results provide a valuable genomic resource to enable the design of precision medicine for MFS. Nature Publishing Group UK 2018-07-17 /pmc/articles/PMC6050269/ /pubmed/30018380 http://dx.doi.org/10.1038/s41467-018-03891-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Ogura, Koichi
Hosoda, Fumie
Arai, Yasuhito
Nakamura, Hiromi
Hama, Natsuko
Totoki, Yasushi
Yoshida, Akihiko
Nagai, Momoko
Kato, Mamoru
Arakawa, Erika
Mukai, Wakako
Rokutan, Hirofumi
Kawai, Akira
Tanaka, Sakae
Shibata, Tatsuhiro
Integrated genetic and epigenetic analysis of myxofibrosarcoma
title Integrated genetic and epigenetic analysis of myxofibrosarcoma
title_full Integrated genetic and epigenetic analysis of myxofibrosarcoma
title_fullStr Integrated genetic and epigenetic analysis of myxofibrosarcoma
title_full_unstemmed Integrated genetic and epigenetic analysis of myxofibrosarcoma
title_short Integrated genetic and epigenetic analysis of myxofibrosarcoma
title_sort integrated genetic and epigenetic analysis of myxofibrosarcoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050269/
https://www.ncbi.nlm.nih.gov/pubmed/30018380
http://dx.doi.org/10.1038/s41467-018-03891-9
work_keys_str_mv AT ogurakoichi integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT hosodafumie integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT araiyasuhito integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT nakamurahiromi integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT hamanatsuko integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT totokiyasushi integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT yoshidaakihiko integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT nagaimomoko integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT katomamoru integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT arakawaerika integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT mukaiwakako integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT rokutanhirofumi integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT kawaiakira integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT tanakasakae integratedgeneticandepigeneticanalysisofmyxofibrosarcoma
AT shibatatatsuhiro integratedgeneticandepigeneticanalysisofmyxofibrosarcoma